Invasive fungal infections in the critically ill patient

Journal of Pharmacy Practice

Volumn 18, Issue 1, 2005, Pages 9-17

  Martin, Craig A ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

Antifungal; Aspergillus; Candida; Critical illness; Fungi

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; CORTICOSTEROID; CREATININE; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; RAVUCONAZOLE; VORICONAZOLE;

ABDOMINAL SURGERY; ACUTE PANCREATITIS; ANTIMICROBIAL THERAPY; ARTIFICIAL VENTILATION; ASPERGILLUS; BACTERIAL INFECTION; BIOFILM; BLASTOMYCES; BLOOD FLOW; BLOOD VESSEL CATHETERIZATION; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA LUSITANIAE; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDIASIS; CHILL; CHRONIC OBSTRUCTIVE LUNG DISEASE; COCCIDIOIDES; CREATININE BLOOD LEVEL; CRITICAL ILLNESS; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; ENTERIC FEEDING; FEVER; FUNGAL COLONIZATION; GASTROINTESTINAL DISEASE; HISTOPLASMA; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INTENSIVE CARE; JEJUNUM ULCER; KIDNEY PERFUSION; LIVER FAILURE; MENINGITIS; MOULD; MYCOSIS; NONHUMAN; ORGAN TRANSPLANTATION; PARENTERAL NUTRITION; PNEUMOCYSTIS; PROPHYLAXIS; REVIEW; RIGOR; RISK FACTOR; SHOCK; SPLENECTOMY; TOXOPLASMA; VIRUS INFECTION; VISUAL DISORDER;

EID: 12844260053     PISSN: 08971900     EISSN: None     Source Type: Journal    
DOI: 10.1177/0897190004273471     Document Type: Review

References (49)

1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309-317.
2. Olaechea PM, Palomar M, Leon-Gil C, et al. Economic impact of Candida colonization and Candida infection in the critically ill patient. Eur J Clin Microbiol Infect Dis. 2004;23:323-330.
3. Curry CR, Quie PG. Fungal septicemia in patients receiving parenteral hyperalimentation. N Engl J Med. 1971;285:1221-1225.
4. Montgomerie JZ, Edwards JE. Association of infection due to Candida albicans with intravenous hyperalimentation. J Infect Dis. 1978;137:197-201.
5. Pappo I, Polacheck I, Zmora O, Feigin E, Freund HR. Altered gut barrier function to Candida during parenteral nutrition. Nutrition. 1994;10:151-154.
6. Marik PE, Pinsky M. Death by parenteral nutrition. Intensive Care Med. 2003;29:867-869.
7. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis. 1993;167:1247-1251.
8. Calandra T, Bille J, Scheneider R, Mosimann F, Francioli P. Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet. 1989;16:1437-1440.
9. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis. 2003;3:685-702.
10. Solomkin JS, Flohr AB, Quie PG, Simmons RL. The role of candida in intraperitoneal infections. Surgery. 1980;88:524-530.
11. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis. 2002;35:627-630.
12. Hajjeh RA, Sofair AN, Harrison LH, et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol. 2004;42:1519-1527.
13. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis. 2000;30:662-678.
14. Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE program. Diagn Microbiol Infect Dis. 1998;30:121-129.
15. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Diekema DJ. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother. 2002;46:1723-1727.
16. Jabra-Rizk MA, Falkler WA, Meiller TF. Fungal biofilms and drug resistance. Emerg Infect Dis. 2004;10:14-19.
17. Al-Fattani MA, Douglas LJ. Penetration of Candida biofilms by antifungal agents. Antimicrobial Agents Chemother. 2004;48:3291-3297.
18. Nucci M, Anaissie E. Should vascular catheters be removed from all patients with candidemia? An evidence-based review. Clin Infect Dis. 2002;34:591-599.
19. Alvarez-Lerma F, Nolla-Salas J, Leon C, et al. Candiduria in critically ill patients admitted to intensive care medical units. Intensive Care Med. 2003;29:1069-1076.
20. Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken A, Peetermans WE, Van Wijngaerden E. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med. 2004;170:621-625.
21. Fung JJ. Fungal infection in liver transplantation. Transplant Infect Dis. 2002;4(suppl 3):S18-23.
22. Kubak BM. Fungal infection in lung transplantation. Transplant Infect Dis. 2002;4(suppl 3):S24-31.
23. Fishman JA. Overview: fungal infections in the transplant patient. Transplant Infect Dis. 2002;4(suppl 3):S3-11.
24. Rubin RH. Overview: pathogenesis of fungal infections in the organ transplant recipient. Transplant Infect Dis. 2002;4(suppl 3):S12-17.
25. Minari A, Husni R, Avery RK, et al. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transplant Infect Dis. 2002;4:195-200.
26. Munoz P, Guinea J, Pelaez T, Duran C, Blanco JL, Bouza E. Nosocomial invasive aspergillosis in a heart transplant patient acquired during a break in the HEPA air filtration system. Transplant Infect Dis. 2004;6:50-54.
27. Playford E, Webster A, Sorell T, Craig J. Antifungal agents for preventing fungal infections in solid organ transplant recipients. Cochrane Database Syst Rev. 2004;3:CD004291.
28. Sharpe MD, Ghent C, Grant D, Horbay GLA, McDougal J, Colby D. Efficacy and safety of itraconazole prophylaxis for fungal infections after orthotopic liver transplantation: a prospective, randomized, double-blind study. Transplantation. 2003;76:977-983.
29. Munoz P, Rodriguez C, Bouza E, et al. Risk factors of invasive aspergillosis after heart transplantation: protective role of oral itraconazole prophylaxis. Am J Transplant. 2004;4:636-643.
30. Eggimann P, Francioli P, Bille J, et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med. 1999;27:1066-1072.
31. Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis. 2002;35:359-366.
32. Peleg AY, Woods ML. Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients. J Antimicrob Chemother. 2004;54:803-808.
33. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled. BMJ. 2001;322:579-582.
34. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med. 1994;331:1325-1330.
35. Anaissie EJ, Vartivarian SE, Abi-Said D, et al. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med. 1996;101:170-176.
36. Phillips P, Shafran S, Garber G, et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis. 1997;16:337-345.
37. Duswald KH, Penk A, Pittrow L. High-dose therapy with fluconazole >800mg/day. Mycoses. 1997;40:167-277.
38. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347:2020-2029.
39. Cancidas [package insert]. Whitehouse Station, NJ: Merck; 2001.
40. Rapp RP. Changing strategies for the management of invasive fungal infections. Pharmacotherapy. 2004;24:4S-28S.
41. VFend [package insert]. New York, NY: Pfizer; 2002.
42. Saag MS, Graybill JR, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis. 2000;30:710-718.
43. Roling EE, Klepser ME, Wasson A, Lewis RE, Ernst EJ, Pfaller MA. Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafingin (LY 303366) alone and in combination against Candida spp. and Cryptococcus neoformans via time-kill methods. Diagn Microbiol Infect Dis. 2002;43:13-17.
44. Dannaoui E, Afeltra J, Meis JFGM, Verweij PE. In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents. Antimicrob Agents Chemother. 2002;46:2708-2711.
45. Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother. 2002;46:2564-2568.
46. Luque JC, Clemons KV, Stevens DA. Efficacy of micafungin alone or in combination against systemic murine aspergillosis. Antimicrob Agents Chemother. 2003;47:1452-1455.
47. Manavathu EK, Alangaden GJ, Chandrasekar PH. Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus. J Antimicrob Chemother. 2003;51:1423-1425.
48. Louie A, Kaw P, Banerjee P, Liu W, Chen G, Miller MH. Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis. Antimicrob Agents Chemother. 2001;45:485-494.
49. Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis. 2003;36:1221-1228.